Department of General Surgery, Zhejiang Provincial People's Hospital, Hangzhou 310014, China.
Surg Endosc. 2010 May;24(5):1164-9. doi: 10.1007/s00464-009-0744-4. Epub 2009 Dec 22.
Although laparoscopic splenectomy (LS) has become the standard approach for most splenectomy cases, some areas still remain controversial. To date, the indications that preclude LS are not clearly defined. Portal hypertension from liver cirrhosis still is a contraindication to LS in the clinical practice guidelines of the European Association for Endoscopic Surgery published in 2008. This study aimed to evaluate the feasibility of LS for hypersplenism secondary to liver cirrhosis and portal hypertension.
The study retrospectively analyzed 206 laparoscopic splenectomies performed for a variety of indications over 13 years. According to diagnosis, the patients were divided into group A (hypersplenism secondary to liver cirrhosis and portal hypertension, n = 96) and group B (hematologic and other disorders, n = 110). A detailed review of medical records was conducted. The perioperative data for the two groups were compared including patient characteristics, diagnosis, operative details, complication rates, and postoperative hospital stay.
Laparoscopic splenectomy was completed for 201 patients. Conversion from laparoscopic to open surgery was necessary for 5 patients (2.4%) because of hemorrhage, and 26 patients (12.6%) had complications. There were significant differences between groups A and B in terms of mean operation time (2.8 vs. 2.1 h), complication rates (17.7% vs. 8.2%), and postoperative stay (7.1 vs. 4.7 days). However, the two groups showed no significant differences with respect to intraoperative blood loss, blood transfusion, and conversion rate.
Laparoscopic splenectomy is a feasible, effective, and safe surgical procedure for patients who require splenectomy. Hypersplenism secondary to cirrhosis and portal hypertension should not be considered contraindications for LS.
虽然腹腔镜脾切除术(LS)已成为大多数脾切除术的标准方法,但仍有一些领域存在争议。迄今为止,LS 的禁忌证尚未明确界定。2008 年,欧洲内镜外科学会发布的临床实践指南中,肝硬化引起的门脉高压仍然是 LS 的禁忌证。本研究旨在评估 LS 治疗肝硬化和门脉高压引起的脾功能亢进的可行性。
本研究回顾性分析了 13 年来因各种适应证行 206 例 LS 的病例。根据诊断,患者分为 A 组(肝硬化和门脉高压引起的脾功能亢进,n=96)和 B 组(血液系统和其他疾病,n=110)。详细查阅病历。比较两组患者的围手术期数据,包括患者特征、诊断、手术细节、并发症发生率和术后住院时间。
腹腔镜脾切除术完成 201 例。5 例(2.4%)因出血需转为开腹手术,26 例(12.6%)发生并发症。A 组和 B 组的手术时间(2.8 vs. 2.1 h)、并发症发生率(17.7% vs. 8.2%)和术后住院时间(7.1 vs. 4.7 d)有显著差异。但两组在术中出血量、输血和中转率方面无显著差异。
LS 是一种可行、有效、安全的手术方法,适用于需要脾切除术的患者。肝硬化和门脉高压引起的脾功能亢进不应视为 LS 的禁忌证。